Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

about

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

Item

http://www.wikidata.org/entity/Q57821741

description

scientific article published on 23 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@en

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@nl

type

Item

label

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@en

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@nl

prefLabel

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@en

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@nl

P1476

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

@en

P2093

Bjørn Tore Gjertsen

http://www.w3.org/2001/XMLSchema#string

Jørn Skavland

http://www.w3.org/2001/XMLSchema#string

Randi Hovland

http://www.w3.org/2001/XMLSchema#string

Stein-Erik Gullaksen

http://www.w3.org/2001/XMLSchema#string

Tobias Gedde-Dahl

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?

Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.

Clinical and biological predictors of outcome following relapse of CML post-allo-SCT

Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.

P304

2045985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1155/2018/2045985

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Håkon Reikvam

Øystein Bruserud

P577

2018-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30345125

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

6174736

http://www.w3.org/2001/XMLSchema#string